221 related articles for article (PubMed ID: 10680665)
1. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
2. Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients?
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
Hepatol Res; 2001 Feb; 19(2):144-157. PubMed ID: 11164739
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
4. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
5. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
6. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
7. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
Ninomiya T; Yoon S; Hayashi Y; Sugano M; Kumon Y; Seo Y; Shimizu K; Kasuga M
J Gastroenterol Hepatol; 1998 Jan; 13(1):68-74. PubMed ID: 9737575
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
[TBL] [Abstract][Full Text] [Related]
11. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.
Kojima H; Hongo Y; Harada H; Inoue T; Miyaji K; Kashiwagi M; Momose T; Arisaka Y; Fukui H; Murai S; Tokita H; Kamitsukasa H; Yagura M; Katsu K
J Gastroenterol Hepatol; 2001 Sep; 16(9):1015-21. PubMed ID: 11595066
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
[TBL] [Abstract][Full Text] [Related]
13. Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C.
Kobayashi M; Ikeda K; Akuta N; Someya T; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Chayama K; Kumada H
Intervirology; 2000; 43(3):174-9. PubMed ID: 11044811
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
15. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
16. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
17. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
[TBL] [Abstract][Full Text] [Related]
20. Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group.
Ouzan D; Babany G; Valla D; Opolon P
J Viral Hepat; 1998 Jan; 5(1):53-9. PubMed ID: 9493517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
